Real-world studies evaluate the effectiveness of Shujin Jianwaiwan in the treatment of lumbar disc herniation, Efficacy and safety of lumbar spinal stenosis and other pain disorders

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300074105

Enrollment

Unknown

Registered

2023-07-31

Start date

2023-07-31

Completion date

Unknown

Last updated

2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar disc herniation/lumbar spinal stenosis

Interventions

Exposed group (Use soothing muscle and strengthening waist pills):NA

Non-exposed group (Do not use soothing muscle and strengthening waist pills):NA

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients with lumbago accompanied by lumbago and knee weakness with definite diagnosis of lumbar disc herniation/lumbar spinal stenosis; (2) Pain VAS score =4 points within 24 hours; (3) Age 18-80 years old, gender is not limited;

Exclusion criteria

Exclusion criteria: (1) Lumbar and leg pain caused by lumbar tuberculosis, lumbar tumors, visceral diseases, etc., or complete disc herniation and prolapse; (2) Chronic liver disease history and abnormal liver biochemical indexes; (3) Other researchers think that it is not appropriate to participate in this researcher;

Design outcomes

Primary

Measure	Time frame
Pain VAS score;	—

Secondary

Measure	Time frame
Low back pain dysfunction index;European five-dimensional Health Scale;Symptoms and signs/TCM syndrome efficacy;	—

Countries

China

Contacts

Public ContactWeiheng Chen

The Third Affiliated Hospital of Beijing University of Chinese Medicine

liuhanfei@zyyjypj.cn+86 139 3037 0172

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026